Page 19 - Expanded Access Protocol News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article RADNOR, Pa. and GENEVA, Switzerland, Dec. 30, 2020 /PRNewswire/  NeuroRx, Inc. and RELIEF THERAPEUTICS Holding AG (SIX: RLF,OTCQB: RLFTF) ( Relief ) today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI™ (previously RLF-100 TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top line data are expected in late January - early February 2021. With FDA s authorization and the extraordinary dedication of our twelve clinical trial sites, we were able to take a drug not formulated or administered to patients in IV form since 2005 and advance it to the clinic in ten weeks. We hope that the highly encouraging results seen in the most critically-ill COVID-19 patients treat

United statesEli lillyAnne hennecke brittney sojevaJonathanc javittDavid schullRaghuram ram selvarajuRobert besthofJonathan javittBrian korbMc servicesRusso partnersSwiss exchangeStony brook universityBig rock partners acquisition corpNeurorx incSpain division